Latest Ratios: P/E Ratio -0.2x · EV/EBITDA N/A · ROE -110.6%. (2019–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $3M | $256M | $303M | $593M | $2.4B | — | — | — |
| Enterprise Value | $-2590865 | $251M | $311M | $598M | $2.3B | — | — | — |
| P/E Ratio → | -0.15 | — | — | — | — | — | — | — |
| P/S Ratio | 3.17 | 313.95 | 119.92 | 10139.74 | — | — | — | — |
| P/B Ratio | 0.15 | 16.24 | 31.50 | 422.09 | 105.51 | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 307.61 | 123.41 | 10230.93 | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 77.6% | 77.6% | 41.8% | -1927.9% | — | — | — | — |
| Operating Margin | -778.2% | -778.2% | -2238.0% | -61634.5% | — | — | — | — |
| Net Profit Margin | -1721.0% | -1721.0% | -2325.2% | -63986.5% | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| ROE | -110.6% | -110.6% | -1065.7% | -314.5% | -112.6% | -110.6% | -29.8% | -13.7% |
| ROA | -52.8% | -52.8% | -101.5% | -65.7% | -91.3% | -86.6% | -29.4% | -13.5% |
| ROIC | -32.8% | -32.8% | -336.9% | -1603.3% | — | — | -653.0% | — |
| ROCE | -49.4% | -49.4% | -140.8% | -77.7% | -113.1% | -110.4% | -30.2% | -14.7% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.00 | 0.00 | 0.98 | 7.04 | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.33 | 0.92 | 3.80 | -1.15 | -1.33 | -0.91 | -1.01 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — |
| Interest Coverage | -17.68 | -17.68 | -41.44 | -54.72 | — | — | — | — |
Net cash position: cash ($5M) exceeds total debt ($48774)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.66 | 0.66 | 0.05 | 0.34 | 6.69 | 1.88 | 66.94 | 79.98 |
| Quick Ratio | 0.65 | 0.65 | 0.05 | 0.32 | 6.69 | 1.88 | 66.94 | 79.98 |
| Cash Ratio | 0.57 | 0.57 | 0.04 | 0.26 | 6.57 | 1.18 | 62.75 | 79.87 |
| Asset Turnover | — | 0.03 | 0.09 | 0.00 | — | — | — | — |
| Inventory Turnover | 1.22 | 1.22 | 22.93 | 3.26 | — | — | — | — |
| Days Sales Outstanding | — | 132.89 | 13.93 | 934.78 | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | 0.1% | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.1% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $3M | $113050 | $17612 | $12632 | $11372 | $11372 | $11372 |
Includes 30+ ratios · 7 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ONCO stock.
Onconetix, Inc.'s current P/E ratio is -0.2x. This places it at the 50th percentile of its historical range.
Onconetix, Inc.'s return on equity (ROE) is -110.6%. The historical average is -115.3%.
Based on historical data, Onconetix, Inc. is trading at a P/E of -0.2x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Onconetix, Inc. has 77.6% gross margin and -778.2% operating margin.
Key Metrics
Top Statement Risk
Imminent liquidity and survival
Metrics are mathematically derived from official filings.
Distressed Valuation Reflects Operational Uncertainty
According to recent market data, ONCO trades at a price-to-sales ratio of 0.75, a multiple that appears to reflect the market's deep skepticism regarding the company's ability to achieve commercial scale for its Entadfi asset rather than any underlying growth potential or intrinsic value.
The low P/S multiple suggests that investors are pricing the company as a distressed asset rather than a growth-stage biotechnology firm. This valuation level warrants caution, as it implies that the market assigns little to no terminal value to the pipeline, focusing instead on the immediate risk of equity dilution required to sustain operations.
Negative Margins Underscore Structural Imbalance
As reported in financial statements, the company's operating margin of -778.16% highlights a fundamental disconnect between the high fixed costs of commercial infrastructure and the minimal revenue generated, suggesting that current earning power is non-existent and likely to remain negative in the near term.
While gross margins have shown volatility, the persistent operating losses indicate that the company has yet to achieve the necessary prescription volume to cover its overhead. Investors should monitor whether management can rationalize the cost structure, as the current margin profile is unsustainable for a standalone commercial entity.
Capital Efficiency Remains Severely Impaired
Based on the reported figures, the return on invested capital has consistently trended in negative territory, with the most recent quarterly ROIC of -16.6% illustrating that the company is currently destroying shareholder value rather than compounding it through its commercial and R&D investments.
The inability to generate positive returns on capital suggests that the pivot to a commercial-stage model has not yet yielded the expected efficiency gains. This trend warrants further investigation into whether the current asset base can ever be optimized to produce positive economic value for shareholders.
Working Capital Cycles Signal Inefficiency
According to quarterly data, the cash conversion cycle remains deeply negative and erratic, with DSO figures reaching 714 days in 2026Q1, which indicates significant friction in the company's ability to collect on sales and manage its working capital effectively within the US market.
Such extreme fluctuations in the cash conversion cycle suggest that the company's operational processes are not yet optimized for a commercial-stage pharmaceutical business. This inefficiency exacerbates the existing cash burn, as the company is forced to tie up precious liquidity in receivables and inventory that are not turning over at a competitive rate.
Misapplied Focus on Revenue Multiples
The most commonly misapplied metric for this business model is the price-to-sales ratio, which obscures the reality that revenue is currently a secondary indicator compared to the company's cash runway and the underlying burn rate of its commercial infrastructure.
Investors should prioritize cash-to-burn ratios over revenue multiples, as the latter fails to account for the high probability of dilutive financing events. Relying on P/S in this context may lead to a false sense of security regarding the company's valuation, as it ignores the existential risk posed by the current liquidity position.